Drug Trial Radar · NCT00589303
AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study
Last checked: Nov 19, 2026Latest source record: Apr 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
27
Actual
Start
Dec 2007
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medtronic
- First posted
- Jan 9, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF).
Conditions
- Atrial Fibrillation
- Heart Failure
Interventions
FDA approved rate and rhythm control drugsDrug
Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion. Rate Control: Beta-Blocker: * metoprolol * atenolol * carvedilol Calcium Channel Blocker: * verapamil * diltiazem Rhythm Control: * procainamide * quinidine * disopyramide * propafenone * flecainide * sotalol * dofetilide * amiodarone
AV Node ablation and device implantDevice
Pacing Systems: * Enpusle Premarket Approval Number (PMA#) P980035 * EnRhythm PMA# P980035 * Adapta PMA# P980035 Cardiac Resynchronization Therapy (CRT) Pacing Systems: \- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031 Implantable Cardioverter-Defibrillator (ICD) Pacing Systems: * EnTrust PMA# P980016 * Virtuoso PMA# P980016 ICD CRT Pacing Systems: * InSync Maximo PMA# P980016 * InSync Sentry PMA# P890003 * Concerto PMA# P980016
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cardiac Hospitalization Within Six Months of EnrollmentTime frame: Six months after enrollment
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Scottsdale, Arizona
The Heart Group
Evansville, Indiana
Mayo Clinic
Rochester, Minnesota
Oregon Health and Science University
Portland, Oregon
Chattanooga Heart Institute
Chattanooga, Tennessee
University of Calgary and Calgary Health Region
Calgary, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.